176
Participants
Start Date
May 31, 2010
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
Omalizumab
Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
Placebo
Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
Asthma therapies
Participants could receive 1 or more of the following medications as concomitant asthma therapy: Inhaled corticosteroids; long acting beta-agonists; zafirlukast or other leukotriene receptor antagonist; zileuton or other 5-lipoxygenase enzyme inhibitors; oral, inhaled, and/or nasal anticholinergic therapy; mast-cell stabilizers; theophyllines; chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.
New York
Staten Island
The Bronx
The Bronx
The Bronx
Mount Vernon
Middletown
Mineola
Rockville Centre
Albany
Newburgh
New Paltz
Olean
Beaver
Pittsburgh
Pittsburgh
Altoona
Carlisle
Harrisburg
Upland
Gaithersburg
Ellicott City
Baltimore
Richmond
Wheeling
High Point
Asheville
Greenville
Gainesville
Albany
Columbus
Pensacola
West Palm Beach
Loxahatchee Groves
Tampa
Bay Pines
Clearwater
Ocala
Huntsville
Knoxville
Lexington
Beavercreek
Centerville
Fort Wayne
Fort Wayne
Madison
Fargo
Fargo
Park Ridge
Chicago
Glen Carbon
Sasint Louis
St Louis
St Louis
Liberty
Springfield
Overland Park
Topeka
Bellevue
Omaha
Metairie
Mandeville
Little Rock
Oklahoma City
Tulsa
Heath
Garland
Dallas
Dallas
San Antonio
San Antonio
Round Rock
El Paso
Centennial
Thornton
Los Angeles
Los Angeles
Granada Hills
Studio City
Bakersfield
Fresno
Fresno
Redwood City
San Francisco
San Mateo
Napa
Walnut Creek
Sacramento
Tacoma
Spokane
Waterbury
Boston
Gardner
North Dartmouth
Taunton
Cranford
Edison
Hillsborough
Verona
Lincoln
Lead Sponsor
Genentech, Inc.
INDUSTRY